Form 4: Halozyme Therapeutics SVP, Chief Technical Officer Michael J. LaBarre Reports Stock Transactions

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports multiple transactions involving common stock, including option exercises and sales, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 23 and 24, 2024, Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed several transactions involving the company's common stock.
• These transactions included the exercise of options to purchase common stock at prices of $8.11 and $16.65, and the subsequent sale of those shares on the open market.
• The sales were conducted at weighted average prices ranging from $54.463 to $55.265 on July 23, and at a weighted average price of $55.115 on July 24.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2023.
• Following these transactions, LaBarre directly owns 168,176 shares of Halozyme Therapeutics common stock and 51,861 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-arranged trading plan and do not necessarily reflect a change in the executive's view of the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, transactions under 10b5-1 plans are less informative as they are pre-arranged.

Comparison to Industry Standards

• Comparing the stock sales to similar transactions by executives at comparable biotechnology companies would require analyzing their Form 4 filings.
• Generally, the use of 10b5-1 plans is a common practice among executives to diversify their holdings and avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small volume of shares involved.

Key Dates